Project Grant R03AG098212
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $312K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute on Aging awarded the University of Texas Medical Branch at Galveston $1.788 million on January 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the interplay between microglia and tau oligomer polymorphs in cognitive resilience among individuals with Alzheimer's disease neuropathology who remain cognitively intact. The project tests the hypothesis that brain-derived tau oligomers isolated from cognitively resilient individuals exhibit reduced toxicity...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $1,308,220 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epigenetic modulation by Enhancer of Zeste Homolog 2 (EZH2) in cerebral amyloid angiopathy and Alzheimer's disease. The research examines how EZH2, a master epigenetic modifier, controls endothelial nitric oxide synthase (eNOS) and claudin-5 tight-junction protein expression in cerebral vasculature. The...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded The University of Texas Southwestern Medical Center $249,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and validate an innovative genetic platform for de-risking g-secretase modulator therapeutics in Alzheimer's disease. The award funds two primary aims. Aim 1 involves using CRISPR/Cas9 engineering and structure-informed design to generate and validate a novel...
- The National Institute on Aging awarded The University of Texas Southwestern Medical Center $456,500 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of heparan sulfate proteoglycans in tau uptake in cell and mouse models as a potential treatment pathway for Alzheimer's disease. The research addresses gaps in understanding how heparan sulfate proteoglycans drive tau uptake in neurons and microglia, which are the brain cell types most affected in...
- The National Institute on Aging awarded Texas Tech University $447,541 on February 1, 2026, under the Aging Research program (CFDA 93.866, assistance type: Project Grant) to investigate microRNA-driven mitochondrial dysfunction in Alzheimer's disease. The research focuses on validating microRNA PC-5P-12969 as both a biomarker for early Alzheimer's diagnosis and a potential therapeutic target. The recipient will measure microRNA PC-5P-12969 levels in blood, cerebrospinal fluid, and postmortem...
- The National Institute on Aging awarded the University of Texas at Dallas $761,537 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate a novel astrocyte endfoot protein arising from translational readthrough and its role in Alzheimer's disease pathology. The research develops loss-of-function and gain-of-function mouse models to characterize AQP4X, an extended isoform of aquaporin 4 that arises when approximately 20 percent of translating ribosomes continue past...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $417,800 on September 15, 2025, for Project Grant R21AG091823 under the Aging Research program (CFDA 93.866). The award funds investigation of senescence induced by iron overload in brain vasculature, with particular focus on sex-dependent differences in vulnerability to iron-induced endothelial damage. The research employs an iron overload model in aged mice, examining the role of the ROBO4...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging awarded Baylor College of Medicine $101,052 under the Aging Research program (CFDA 93.866) on December 25, 2026, to characterize the role of CARHSP1 (calcium-regulated heat stable protein 1) in the aging brain and Alzheimer's disease. The funded research will define the role of CARHSP1 and its Drosophila homolog CG9705 in normal neuronal function through loss- and gain-of-function modeling; identify genetic interactions that mediate CARHSP1-induced toxicity by...
- The National Institute on Aging awarded the University of Texas at Austin $10.686 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate remotely-supervised neuromodulation paired with language treatment for the logopenic variant of primary progressive aphasia, a progressive language disorder caused by underlying Alzheimer's disease pathology. The award supports research to enhance proven language treatment for LVPPA by combining it with tailored, home-based...